Page last updated: 2024-09-05

tesaglitazar and Angioma

tesaglitazar has been researched along with Angioma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berg, AL; Blomgren, B; Evans, J; Hellmold, H; Lindblom, P; Lundgren, H; Marcusson-Ståhl, M; Öhman, P; Sjögren, N; Skånberg, I; Tugwood, J; Westerberg, R; Zhang, H	1

Other Studies

1 other study(ies) available for tesaglitazar and Angioma

Article	Year
Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies. Toxicologic pathology, 2012, Volume: 40, Issue:1 Topics: Alkanesulfonates; Animals; Area Under Curve; Carcinogenicity Tests; Cell Proliferation; Cricetinae; Female; Gene Expression Profiling; Hemangioma; Hemangiosarcoma; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Male; Phenylpropionates; PPAR alpha; PPAR gamma; Statistics, Nonparametric; Vascular Endothelial Growth Factor A	2012

Article

Year

Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.

Toxicologic pathology, 2012, Volume: 40, Issue:1

Topics: Alkanesulfonates; Animals; Area Under Curve; Carcinogenicity Tests; Cell Proliferation; Cricetinae; Female; Gene Expression Profiling; Hemangioma; Hemangiosarcoma; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Male; Phenylpropionates; PPAR alpha; PPAR gamma; Statistics, Nonparametric; Vascular Endothelial Growth Factor A

2012